Table 1.
Baseline patient characteristics for medical admissions pre and post introduction of molecular point-of-care testing (mPOCT).
| Pre mPOCTgroupn = 1988 | Post mPOCTgroupn = 4640 | Difference(95%CI) | p valuea | |
|---|---|---|---|---|
| Age, years | 75.2 [57.5–85.3] | 73.9 [54.0–84.8] | 1.4 (1.1–1.6) | 0.0019 |
| Male Sex | 1023 (51.5%) | 2527 (54.5%) | 3% (2.2 – 3.8) | 0.0265 |
| BMIb | 26.0[22.28–30.06] | 26.1[22.49–30.27] | 0.2 (0.1–0.3) | 0.2799 |
| BAMEc | 87 (4.6%) | 220 (5.1%) | 0.5% (0.2–0.8) | 0.4611 |
| Asthma | 280 (14.1%) | 478 (10.3%) | 3.8% (3.1–4.4) | < 0.0001 |
| COPD | 332 (16.7%) | 477 (10.3%) | 6.4% (5.7–7.2) | < 0.0001 |
| CKD | 15 (0.8%) | 27 (0.6%) | 0.2% (0.0–0.4) | 0.5204 |
| Diabetes | 198 (10.0%) | 340 (7.3%) | 2.6% (2.1–3.2) | 0.0004 |
| Dementia | 48 (2.4%) | 61 (1.3%) | 1.1% (0.8–1.5) | 0.0018 |
| Hypertension | 861 (43.3%) | 1354 (29.2%) | 14.1% (13.3 15.0) | < 0.0001 |
| IHD | 272 (13.7%) | 417 (9.0%) | 4.7% (4.0–5.4) | < 0.0001 |
| CCF | 170 (8.6%) | 211 (4.6%) | 4.0% (3.4–4.6) | < 0.0001 |
| Cirrhosis | 101 (5.1%) | 123 (2.7%) | 2.4% (1.9–2.9) | < 0.0001 |
| CCI | 3.7 (1.7–5.7) | 3.1 (1.2–5.0) | 0.54 (0.5–0.6) | < 0.0001 |
All data are presented as n (%), median [interquartile range] or mean (SD). CI, confidence interval. BMI, body mass index. BAME, black and minority ethic. COPD, chronic obstructive airways disease. CKD, chronic kidney disease. IHD, ischaemic heart disease. CCF, congestive cardiac failure. CCI, Charlson comorbidity index.
a
Mann Whitney U Test, Chi squared or Fisher's Exact Test.
b
Assessed in 1561 and 1946 patients in the pre and post implementation groups, respectively.
c
Assessed in 1902 and 4357 patients in the pre and post implementation groups, respectively.